Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Telemedicine delivery of patient education in remote Ontario communities: feasibility of an Advanced Clinician Practitioner in Arthritis Care (ACPAC)-led inflammatory arthritis education program.

Warmington K, Flewelling C, Kennedy CA, Shupak R, Papachristos A, Jones C, Linton D, Beaton DE, Lineker S.

Open Access Rheumatol. 2017 Feb 24;9:11-19. doi: 10.2147/OARRR.S122015. eCollection 2017.

2.

Symptom Resolution and Patient-Perceived Recovery Following Ankle Arthroplasty and Arthrodesis.

Pinsker E, Inrig T, Daniels TR, Warmington K, Beaton DE.

Foot Ankle Int. 2016 Dec;37(12):1269-1276. Epub 2016 Aug 11.

PMID:
27521356
3.

A prospective comparison of telemedicine versus in-person delivery of an interprofessional education program for adults with inflammatory arthritis.

Kennedy CA, Warmington K, Flewelling C, Shupak R, Papachristos A, Jones C, Linton D, Beaton DE, Lineker S, Hogg-Johnson S.

J Telemed Telecare. 2017 Feb;23(2):197-206. doi: 10.1177/1357633X16635342. Epub 2016 Jul 9.

PMID:
26957111
4.

Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.

Lloyd SA, Morony SE, Ferguson VL, Simske SJ, Stodieck LS, Warmington KS, Livingston EW, Lacey DL, Kostenuik PJ, Bateman TA.

Bone. 2015 Dec;81:562-572. doi: 10.1016/j.bone.2015.08.021. Epub 2015 Aug 28.

PMID:
26318907
5.

The patient perspective: arthritis care provided by Advanced Clinician Practitioner in Arthritis Care program-trained clinicians.

Warmington K, Kennedy CA, Lundon K, Soever LJ, Brooks SC, Passalent LA, Shupak R, Schneider R.

Open Access Rheumatol. 2015 Aug 19;7:45-53. eCollection 2015.

6.

Reliability and validity of 6 measures of pain, function, and disability for ankle arthroplasty and arthrodesis.

Pinsker E, Inrig T, Daniels TR, Warmington K, Beaton DE.

Foot Ankle Int. 2015 Jun;36(6):617-25. doi: 10.1177/1071100714566624. Epub 2015 Feb 4.

PMID:
25652665
7.

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.

Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ.

Endocrinology. 2014 Dec;155(12):4785-97. doi: 10.1210/en.2013-1905. Epub 2014 Sep 26.

PMID:
25259718
8.
9.

Understanding osteoporosis and fractures: an introduction to the use of qualitative research.

Hoang-Kim A, Schemitsch E, Sale JE, Beaton D, Warmington K, Kulkarni AV, Reeves S.

Arch Orthop Trauma Surg. 2014 Feb;134(2):207-17. doi: 10.1007/s00402-013-1799-1. Epub 2013 Jul 17.

PMID:
23860671
10.

Evaluation of perceived collaborative behaviour amongst stakeholders and clinicians of a continuing education programme in arthritis care.

Lundon K, Kennedy C, Rozmovits L, Sinclair L, Shupak R, Warmington K, Passalent L, Brooks S, Schneider R, Soever L.

J Interprof Care. 2013 Sep;27(5):401-7. doi: 10.3109/13561820.2013.783559. Epub 2013 May 16.

PMID:
23679675
11.

The ability of outcome questionnaires to capture patient concerns following ankle reconstruction.

Pinsker E, Daniels TR, Inrig T, Warmington K, Beaton DE.

Foot Ankle Int. 2013 Jan;34(1):65-74. doi: 10.1177/1071100712460365.

PMID:
23386763
12.

Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury.

Roudier M, Li X, Niu QT, Pacheco E, Pretorius JK, Graham K, Yoon BR, Gong J, Warmington K, Ke HZ, Black RA, Hulme J, Babij P.

Arthritis Rheum. 2013 Mar;65(3):721-31. doi: 10.1002/art.37802.

13.

Prescription for education: development, evaluation, and implementation of a successful interprofessional education program for adults with inflammatory arthritis.

Kennedy CA, Beaton DE, Warmington K, Shupak R, Jones C, Hogg-Johnson S.

J Rheumatol. 2011 Oct;38(10):2247-57. doi: 10.3899/jrheum.101307. Epub 2011 Jul 15.

PMID:
21765108
14.

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.

Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.

Endocrinology. 2011 Sep;152(9):3312-22. doi: 10.1210/en.2011-0252. Epub 2011 Jul 5.

PMID:
21733832
15.

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.

Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.

J Bone Miner Res. 2010 Dec;25(12):2647-56. doi: 10.1002/jbmr.182. Epub 2010 Jul 16. Erratum in: J Bone Miner Res. 2011 Feb;26(2):439.

16.

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ.

Bone. 2009 Oct;45(4):669-76. doi: 10.1016/j.bone.2009.06.011. Epub 2009 Jun 17.

PMID:
19539794
17.

One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength.

Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ.

J Bone Miner Res. 2009 Jul;24(7):1234-46. doi: 10.1359/jbmr.090215.

18.

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C.

J Bone Miner Res. 2009 Apr;24(4):578-88. doi: 10.1359/jbmr.081206.

19.

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK.

J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112.

20.

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ.

J Bone Miner Res. 2008 May;23(5):672-82. doi: 10.1359/jbmr.080109.

21.

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C.

J Bone Miner Res. 2008 Jun;23(6):860-9. doi: 10.1359/jbmr.080216.

22.

Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.

Kostenuik PJ, Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, Adamu S, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, Lacey D.

J Bone Miner Res. 2007 Oct;22(10):1534-47.

23.

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan HL, Capparelli C, Starnes C, Weimann B, Dunstan CR, Kostenuik PJ.

Endocrinology. 2005 Aug;146(8):3235-43. Epub 2005 Apr 21.

PMID:
15845617
24.

CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin.

Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S, Manoukian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ, Senaldi G.

Gut. 2005 Jan;54(1):78-86. Erratum in: Gut. 2005 Feb;54(2):316. Manuokian, R [corrected to Manoukian, R].

25.

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ.

J Bone Miner Res. 2003 May;18(5):852-8.

27.

Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation.

Chensue SW, Warmington KS, Allenspach EJ, Lu B, Gerard C, Kunkel SL, Lukacs NW.

J Immunol. 1999 Jul 1;163(1):165-73.

28.

Effect of C-C chemokine receptor 2 (CCR2) knockout on type-2 (schistosomal antigen-elicited) pulmonary granuloma formation: analysis of cellular recruitment and cytokine responses.

Warmington KS, Boring L, Ruth JH, Sonstein J, Hogaboam CM, Curtis JL, Kunkel SL, Charo IR, Chensue SW.

Am J Pathol. 1999 May;154(5):1407-16.

29.

Expression and participation of eotaxin during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granuloma formation.

Ruth JH, Lukacs NW, Warmington KS, Polak TJ, Burdick M, Kunkel SL, Strieter RM, Chensue SW.

J Immunol. 1998 Oct 15;161(8):4276-82.

30.

Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice: analysis of local and regional cytokine and chemokine networks.

Chensue SW, Warmington K, Ruth JH, Lukacs N, Kunkel SL.

J Immunol. 1997 Oct 1;159(7):3565-73. Erratum in: J Immunol 1999 Mar 1;162(5):3106.

PMID:
9317156
31.

Transgene-induced production of IL-4 alters the development and collagen expression of T helper cell 1-type pulmonary granulomas.

Lukacs NW, Addison CL, Gauldie J, Graham F, Simpson K, Strieter RM, Warmington K, Chensue SW, Kunkel SL.

J Immunol. 1997 May 1;158(9):4478-84.

PMID:
9127014
32.

Differential recruitment of leukocyte populations and alteration of airway hyperreactivity by C-C family chemokines in allergic airway inflammation.

Lukacs NW, Strieter RM, Warmington K, Lincoln P, Chensue SW, Kunkel SL.

J Immunol. 1997 May 1;158(9):4398-404.

PMID:
9127004
35.

IL-1 receptor antagonist (IL-1ra) expression, function, and cytokine-mediated regulation during mycobacterial and schistosomal antigen-elicited granuloma formation.

Ruth JH, Bienkowski M, Warmington KS, Lincoln PM, Kunkel SL, Chensue SW.

J Immunol. 1996 Apr 1;156(7):2503-9.

PMID:
8786311
36.

In vivo regulation of macrophage IL-12 production during type 1 and type 2 cytokine-mediated granuloma formation.

Chensue SW, Ruth JH, Warmington K, Lincoln P, Kunkel SL.

J Immunol. 1995 Oct 1;155(7):3546-51.

PMID:
7561051
37.
38.

Monocyte chemotactic protein expression during schistosome egg granuloma formation. Sequence of production, localization, contribution, and regulation.

Chensue SW, Warmington KS, Lukacs NW, Lincoln PM, Burdick MD, Strieter RM, Kunkel SL.

Am J Pathol. 1995 Jan;146(1):130-8.

39.
41.

Inflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1.

Lukacs NW, Chensue SW, Strieter RM, Warmington K, Kunkel SL.

J Immunol. 1994 Jun 15;152(12):5883-9.

PMID:
7911491
42.

Production of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 alpha by inflammatory granuloma fibroblasts.

Lukacs NW, Chensue SW, Smith RE, Strieter RM, Warmington K, Wilke C, Kunkel SL.

Am J Pathol. 1994 Apr;144(4):711-8.

43.

Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response.

Chensue SW, Bienkowski M, Eessalu TE, Warmington KS, Hershey SD, Lukacs NW, Kunkel SL.

J Immunol. 1993 Oct 1;151(7):3654-62.

PMID:
8376799
44.

Evolving T cell responses in murine schistosomiasis. Th2 cells mediate secondary granulomatous hypersensitivity and are regulated by CD8+ T cells in vivo.

Chensue SW, Warmington KS, Hershey SD, Terebuh PD, Othman M, Kunkel SL.

J Immunol. 1993 Aug 1;151(3):1391-400.

PMID:
8335935
45.

The role of macrophage inflammatory protein 1 alpha in Schistosoma mansoni egg-induced granulomatous inflammation.

Lukacs NW, Kunkel SL, Strieter RM, Warmington K, Chensue SW.

J Exp Med. 1993 Jun 1;177(6):1551-9.

46.
47.

Role of IL-4 and IFN-gamma in Schistosoma mansoni egg-induced hypersensitivity granuloma formation. Orchestration, relative contribution, and relationship to macrophage function.

Chensue SW, Terebuh PD, Warmington KS, Hershey SD, Evanoff HL, Kunkel SL, Higashi GI.

J Immunol. 1992 Feb 1;148(3):900-6.

PMID:
1309844

Supplemental Content

Loading ...
Support Center